PersPective
Stem cell is a clonal, self-renewing entity that is multipotent and thus can generate several differentiated cell type (describing cellular attributes only) 1 . Increasing understanding of molecular mechanisms governing their potential can help in better understanding and remedy for health problems such as neurodegenerative diseases, heart ailments, cancers and radiation injury etc. Omics analysis of SC has allowed distinguishing the major features that define a cell as SC and, identification of its stemness, differentiation and tissue based niche regulators. Omics data include quantification of mRNA transcripts levels (transcriptome), protein abundance (proteome), metabolic fluxes (fluxome), intracellular and extracellular metabolites concentration (metabolome) and information on protein-protein and protein-DNA interactions (interactome). To efficiently extract relevant biological insight from vast amount of data generated, appropriate and goal-dependent tools are necessary 2 . In order to extrapolate the information stored in omics, drugs and disease database, a new tool is required which could integrate all the available and evolving information and suggests us an optimal solution to a problem (Fig. 1) . This would help us in translating the ever-increasing biological information about SC from benchto-bedside.
At present there are many tools viz. DvD 4 , MeSH 5 , connectivity map 6 , Metacore 7 , etc., which could integrate few of the databases and could query the databases on the basis of user input. Even a database (StemBase) 8 has been created, specifically, to facilitate the discovery of gene's function relevant to SC control and differentiation. Nevertheless, these tools lack capability to integrate all the databases to generate a possible solution. The basic idea is to query the available repositories for the identification of SC specific biomarkers under various milieu and novel drug targets for their fates regulation. This will facilitate repurposing of known chemical/ drug like compounds/ clinically used drugs, for which most of the in vitro data, in vivo data and clinical data is available. The predicted candidate molecules from this tool may find applications in genome based clinical trials, population studies, outcome research and in health care system 9 .
Proposed tool capability
This system will be able to retrieve available data, query it, and generate signature profiles and interaction network from 2 ). For this, individual's clinical data during the course of ageing (from childhood to old age) could be stored temporally in a repository as in vogue practice of stem cell banking for futuristic applications. This information will be vital in case of emergent situation, without wasting time on lengthy diagnostic procedures. However on the flip side, commercialisation of this repository by private firms will make it exclusive for those who could afford this. The identification of signature model deduced from this information would likely to give cues to the underlying molecular mechanism. These pathways may be tweaked in SC using available/ repurposed drugs for regenerating the affected tissue. It would also include analysis of new metabolites generated due to these pathologies (Metabolomics), the survival chances (Disease bank) and the drugs available (Drug bank) for this patient. In addition, descendents of the patients could be counselled for their chances of inheriting similar phenotype and precautions to be taken for mitigating it. The predicted signature would also find utility in in vitro to guide a tissue/organs generation for tissue engineering and increased transplantation efficiency using repurposed-drug-primed SC.
The big data analysis based tissue engineering will be a major turn in the conceptual approach to reconstruction of tissues and organs. In addition, advances in SC biology using multidata analysis would make it possible to engineer tissues which were otherwise not amenable to reconstruction. In totality, hitherto, this type of tool is unavailable however endeavour to achieve this has been initiated in the form of Omic space 10 . It is a coordinate based integration and analysis of genomic phenome interactions. It is available on a public server at http://omicspace.riken.jp (known as PosMed or Positional Medicine). It ranks genes, metabolites, diseases and drugs based on the statistical significance of associations which are connected through biological databases such as MEDLINE, OMIM, pathway, coexpressions, molecular interactions and ontology terms (Fig. 3(a), 3(b) ).
Nevertheless, it is not capable of providing a possible solution; it only suggests a list of interactions which are needed to be mined manually. In the absence of availability of proposed tool, individual databases and an array of analysis tools may be employed to achieve desired output, for example, to get genes, disease, drugs, metabolites and protein interaction ( Table 1 ). The list of databases and analysis tools would keep on increasing along with a new tool employed for a new analysis. And results obtained would be very difficult to understand and integrate from various tools; this warrants need of a single tool which could parse data from multiple databases.
A central database exchanging information with the proposed tool might also result in better understanding of immune compatibility and enhanced methods for matching patient to donor. Nonetheless, this would need to comply with institutional review board (IRB) protocol and may include creation of stem cell standards like minimum information about stem cell experiments (MIASCE) 12 similar to minimum information about a microarray experiment (MIAME) Figure 2. a patient/ population data could act as an input for generating signature profile, which could be compared with the data available in repositories such as gene-expression profiles, snPs data, metabolomics data, proteomics data, sequencing data and imaging data. this data could be correlated with clinical data and treatments available using scs as a source. this system analysis may also include family history and demographics. the optimal solution will help in diagnosis/ prognosis of an individual, drug response, environmental response and the associated risks. the image was generated in cytoscape. the directed edges indicating the techniques/ procedure from which this data was generated.
development of a common tool available to public. In summary, a tool for integrated omics, drugs and clinical SC data analysis will increase the potential of SC to infinity and hitherto untreatable diseases. However, extrapolation of in silico prediction to humans should not be considered without supporting pre-clinical/ clinical data and prior regulatory authority approval, which will otherwise undermine the beneficial uses of this tool. 13 . It is also likely that stem cells therapeutics could benefit from the development of informatics tools that combine existing databases and data sources and compliment these with best practices for collaboration. Following multipronged strategy, all stakeholders are needed to be engaged and ensure funding organisations and regulatory authorities are supportive of this proposal. In addition, stem cell researchers must collaborate to overcome hurdles and strive towards 
